Jurkat-NFAT-Luc2-CAR19-Stable Cell Line
| Catalog Number |
CBCL-0278 |
| Price |
Online Inquiry |
| Unit Quantity |
1 x 10^6 cells / 1.0 ml |
Introduction
This stable Jurkat cell line expresses exogenous human CAR19 and luciferase under the control of the NFAT signaling pathway, enabling studies of CAR19-mediated signaling and NFAT-dependent gene expression.
Application
Drug screening and biological assays
Background
CAR19 is a chimeric antigen receptor that targets CD19, a B cell surface marker. It is used in CAR-T cell therapy for treating B cell malignancies.
Product Information
| Category |
Luciferase Reporter Cell Lines |
| Cell Line Name |
Jurkat-NFAT-Luc2-CAR19-Stable Cell Line |
| Protein Family |
Chimeric antigen receptors family |
| Gene |
CAR19 |
| Species |
Human |
| Host Cell Line |
Jurkat |
| Cell Type |
Human T-cell leukemia |
| Morphology |
Lymphoblastoid |
| Growth Properties |
Suspension |
| Selection Marker |
Hygromycin B |
| Recommended Medium |
RPMI1640+10%FBS+300µg/mL Hygromycin B |
| Freeze Medium |
70% RPMI1640+20% FBS+10% DMSO |
| Storage Method |
Frozen in liquid nitrogen. |
| Stability |
Validated for at least 10 passages |
| Mycoplasma |
Negative |
| Sterility Testing |
Negative |
| Shipping |
Shipping in dry ice |
| Biosafety Level |
BSL-1 |
| Caution |
For Research Use Only |
For research use only. Not for any other purpose.
